The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 08, 2025

Filed:

Jan. 28, 2020
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Andreia Costa, Seattle, WA (US);

Rupesh Amin, Seattle, WA (US);

Jenna Bailey, Seattle, WA (US);

Samriti Bedi, Newcastle, WA (US);

Brian Belmont, Seattle, WA (US);

Aye Chen, Seattle, WA (US);

Stephen Jacob Goldfless, Seattle, WA (US);

Eric Jeffery, Seattle, WA (US);

Yue Jiang, Seattle, WA (US);

Yeonjoo Oh, Seattle, WA (US);

Madeline Williams, Seattle, WA (US);

Collin Hauskins, Seattle, WA (US);

Catherine Sierra, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/49 (2023.05); A61K 2239/55 (2023.05);
Abstract

Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.


Find Patent Forward Citations

Loading…